TAE Technologies to Merge with Trump Media in $6 Billion All-Stock Deal, Pivoting Fusion Strategy to Public Markets

New updates have been reported about TAE Technologies (PC:TAETE)

TAE Technologies is set to become a publicly traded fusion energy player through an all-stock merger with Trump Media & Technology Group (TMTG), valuing the transaction at more than $6 billion and sharply increasing TAE’s strategic and financial flexibility. The combined company, to be led jointly by TMTG CEO Devin Nunes and TAE CEO Dr. Michl Binderbauer as co-CEOs, plans to start siting and construction next year of what it describes as the world’s first 50 MWe utility-scale fusion power plant, followed by larger facilities in the 350–500 MW range. For TAE, which has raised about $2 billion to date from investors including Google, Chevron Technology Ventures and New Enterprise Associates and was last valued around $1.8 billion, the deal significantly uplifts its implied valuation and provides access to TMTG’s $3.1 billion in assets, largely tied to cryptocurrency-related holdings and partnerships. This move comes as power demands from AI-driven data centers surge and as the U.S. Department of Energy rolls out a roadmap for commercial fusion without yet committing new capital, prompting industry concerns about how political and regulatory dynamics could affect funding and project selection.

TAE’s merger with a politically prominent media company introduces both opportunity and risk as the fusion sector remains pre-commercial and technically uncertain. Inside the industry, stakeholders are watching closely for potential conflicts of interest in DOE decision-making given that fusion companies recently lobbied for billions in federal support, while competitors such as Commonwealth Fusion Systems and Helion target grid-scale deployments in the early 2030s. TAE’s technology approach—using magnetic fields generated by rotating plasma, stabilized and driven by external particle beams—has yet to demonstrate net power, and the company has historically struggled to make earlier designs work, underscoring the execution risk behind the new utility-scale commitments. At the same time, TAE has been diversifying its revenue prospects via a life sciences division that repurposes its particle accelerator technology for cancer radiation therapy, potentially providing non-energy income streams as fusion development continues. For executives and investors, the transaction positions TAE at the center of a capital-intensive, highly competitive race to commercial fusion, with public-market scrutiny, politicization risk, and the need to convert an ambitious project pipeline into demonstrable technical and commercial milestones over the next decade.